NORTH WALES, Pa.--(BUSINESS WIRE)-- We commend the FDA for making the recommendation to approve providing women with increased over-the-counter (OTC) access to Plan B One-Step® and we are disappointed that at this late date, the Department of Health and Human Services has come to a different conclusion. We have not yet received the Complete Response Letter at this time. We will review the letter when we receive it and then determine our next steps.
CONTACT:
Media:
Teva USA
Denise Bradley, 215-591-8974
[email protected]
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Other Health FDA General Health
MEDIA: